Prot #WO40242: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-PD-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of Th

Project: Research project

Project Details

StatusActive
Effective start/end date8/21/198/21/22

Funding

  • Genentech, Inc. (Prot #WO40242)